Compositions for treatment of systemic mastocytosis
OwnerPeter Valentinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of the combination of tyrosine phosphate inhibitors AMN107 and PKC412 for the preparation of a drug for the treatment of a mast cell-related proliferative disease. The present invention is also drawn to a combination treatment of a tyrosine phosphate inhibitor and a TK-inhibitor that is effective against a mast cell-related proliferative disease, including especially systemic mastocytosis (SM) including aggressive SM (ASM) and mast cell leukemia (MCL).
Claims15
A method of treating a mast cell-related proliferative disease, comprising administering a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, in combination with a compound of formula (II):
- or pharmaceutically acceptable salts thereof.
A method for treating mammals suffering from systemic mastocytosis comprising administering to a mammal in need of such treatment a KIT-activity inhibiting amount of a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, in combination with a compound of formula (II):
- or pharmaceutically acceptable salts thereof.
A method for treating mammals, including man, suffering from systemic mastocytosis comprising administering to a mammal in need of such treatment a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, in combination with a compound of formula (II):
- or pharmaceutically acceptable salts thereof.
A method of treating a mast cell-related proliferative disease, comprising administering a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, in combination with a tyrosine kinase (TK) inhibitor selected from dasatinib and 2CdA;
- or pharmaceutically acceptable salts thereof.
A method of treating systemic mastocytosis, comprising administering a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, in combination with a tyrosine kinase (TK) inhibitor selected from dasatinib and 2CdA,
- or a pharmaceutically acceptable salt thereof.
A method for treating mammals suffering from a mast cell-related proliferative disease comprising administering to a mammal in need of such treatment a KIT-activity inhibiting amount of a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, in combination with a tyrosine kinase (TK) inhibitor, selected from dasatinib and 2CdA
- or pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.